Ondine Duverger

Ondine Duverger

Auto-generated profile, based on publicly available information

Ondine Duverger

Institut de Recherche en Infectiologie de Montpellier Univ. Montpellier CNRS Montpellier 34293 France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
EJErik Jung
Erik Jung
TGTizian Griesser
Tizian Griesser
JCJordan Costafrolaz
Jordan Costafrolaz
ODOndine Duverger
Ondine Duverger
YMYves Mattenberger
Yves Mattenberger
KGKarl Gademann
Karl Gademann
Peripheral modification is often the main approach to optimize natural products for improved biological activity or desired physicochemical properties. This procedure inevitably increases molecular weight, often accompanied by undesired increased lipophilicity. Removing structural elements from natural products is not always tolerated. This is also the case for the antibiotic fidaxomicin (Fdx), where every structural component has been shown to be crucial for antibiotic activity. In this work, we demonstrate how the residue switching approach can maintain biological activity of Fdx derivatives by replacing the rhamnoside‐dichlorohomoorsellinate moiety of Fdx with smaller, more polar building blocks. We used palladium‐catalysed allylic substitution to selectively install N‐nucleophiles on the core of Fdx. The new derivatives were designed to mimic the binding of Fdx to the bacterial RNA polymerase. Evaluation against Mycobacterium tuberculosis, Clostridioides difficile, and the Gram‐negative model organism Caulobacter crescentus demonstrated that the newly introduced residues can restore antibiotic activity, which was further supported by on‐target RNA polymerase assays. We combined the allylic substitution with an organocatalysed novioside acylation protocol to enable the functionalisation of two vectors on Fdx in one pot. This platform greatly expands the accessible chemical space for Fdx derivatives and enables the future development of systemic Fdx antibiotics.

26 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ODOndine Duverger
Ondine Duverger
ZMZakia Morichaud
Zakia Morichaud
EREmmanuel Roulland
Emmanuel Roulland
SNStephanie Norsikian
Stephanie Norsikian
LCLaurent Chaloin
Laurent Chaloin
KBKonstantin Brodolin
Konstantin Brodolin
Fidaxomicin is a narrow-spectrum antibiotic that inhibits bacterial RNA polymerase (RNAP) at an early stage of transcription initiation. Fidaxomicin is used for treating Clostridioides difficile infections and has demonstrated in vitro efficacy against drug-resistant strains of Mycobacterium tuberculosis (Mtb). Fidaxomicin derivatives are currently the focus of extensive research to develop novel antibacterial agents. Previous studies showed that region 3.2 of the RNAP primary σ factor and the mycobacterial transcriptional activator RbpA modulate fidaxomicin potency through poorly understood mechanisms. Moreover, the impact of the structurally distinct extracytoplasmic function (ECF) σ factors on fidaxomicin potency has never been explored. Here, using DNA scaffold-based in vitro transcription assays, we found that RbpA-dependent primary σ factors from Mtb enhance fidaxomicin potency, whereas ECF σ factors render Mtb RNAP resistant to fidaxomicin. Contrary to the prevailing assumptions, RbpA has only a marginal effect on fidaxomicin potency. Our structural analysis and molecular dynamics simulations support a model in which ECF σ factors obstruct fidaxomicin binding by changing the configuration of the RNAP RNA channel. Conversely, the direct interaction between fidaxomicin and RbpA-dependent primary σ factors does not affect drug binding. Our findings identify the σ factor as a key modulator of fidaxomicin potency and provide a framework to explore σ factor structural diversity for designing pathogen-specific fidaxomicin analogs. Moreover, these results highlight fundamental mechanistic differences between the modes of action of housekeeping and ECF σ factors during transcription initiation.

13 November 2026 in Journal of Molecular Biology
Verified
Journal Article
Open access
ODOndine Duverger
Ondine Duverger
ZMZakia Morichaud
Zakia Morichaud
EREmmanuel Roulland
Emmanuel Roulland
SNStephanie Norsikian
Stephanie Norsikian
LCLaurent Chaloin
Laurent Chaloin
KBKonstantin Brodolin
Konstantin Brodolin

4 December 2024 in Angewandte Chemie
Verified
Journal Article
Open access
EJErik Jung
Erik Jung
TGTizian Griesser
Tizian Griesser
JCJordan Costafrolaz
Jordan Costafrolaz
ODOndine Duverger
Ondine Duverger
YMYves Mattenberger
Yves Mattenberger
KGKarl Gademann
Karl Gademann
Periphere Modifikation ist ein weit verbreiteter Ansatz zur Optimierung von Naturstoffen hinsichtlich biologischer Aktivität oder gewünschter physikochemischer Eigenschaften. Dieses Verfahren führt unweigerlich zu einer Erhöhung des Molekulargewichts, häufig begleitet von größerer Lipophilie. Umgekehrt wird die Entfernung von Strukturelementen aus Naturstoffen nicht immer toleriert: So hat sich jede Strukturkomponente als essenziell für die Wirkung des Antibiotikums Fidaxomicin (Fdx) erwiesen. In dieser Arbeit zeigen wir, dass die biologische Aktivität von Fdx‐Derivaten aufrechterhalten werden kann, wenn der Rhamnosid‐Dichlorohomoorsellinat‐Substituent von Fdx durch kleinere, polarere Bausteine ersetzt wird. Wir installierten selektiv N‐Nukleophile durch eine palladiumkatalysierte allylische Substitution am Makrozyklus von Fdx. Diese neuen Derivate wurden konzipiert, um die Bindung von Fdx an die bakterielle RNA‐Polymerase zu imitieren. Die Evaluierung gegen Mycobacterium tuberculosis, Clostridioides difficile und den Gram‐negativen Modellorganismus Caulobacter crescentus zeigte, dass die neu eingeführten Bausteine die antibiotische Aktivität wiederherstellen können, was durch enzymatische RNA‐Polymerase Assays weiter bestätigt wurde. Ausserdem haben wir die allylische Substitution mit einem organokatalysierten Noviosid‐Acylierungsprotokoll kombiniert, um die Funktionalisierung von zwei Vektoren von Fdx in derselben Reaktionssequenz zu ermöglichen. Diese Plattform erweitert den zugänglichen chemischen Raum für Fdx‐Derivate erheblich und ermöglicht die künftige Entwicklung von systemischen Fdx‐Antibiotika‐Derivaten.